2.21 USD
-0.18 (-7.53%)
Overall CABA gets a fundamental rating of 1 out of 10. We evaluated CABA against 530 industry peers in the Biotechnology industry. CABA has a bad profitability rating. Also its financial health evaluation is rather negative. CABA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
CABA had negative earnings in the past year.
In the past year CABA has reported a negative cash flow from operations.
CABA had negative earnings in each of the past 5 years.
In the past 5 years CABA always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -83.54%, CABA is doing worse than 69.81% of the companies in the same industry.
CABA has a Return On Equity of -113.66%. This is comparable to the rest of the industry: CABA outperforms 42.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -83.54% | ||
| ROE | -113.66% | ||
| ROIC | N/A |
ROA(3y)-44.86%
ROA(5y)-40.06%
ROE(3y)-51.8%
ROE(5y)-45.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CABA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for CABA has been increased compared to 1 year ago.
The number of shares outstanding for CABA has been increased compared to 5 years ago.
The debt/assets ratio for CABA is higher compared to a year ago.
2.2 Solvency
CABA has an Altman-Z score of -2.84. This is a bad value and indicates that CABA is not financially healthy and even has some risk of bankruptcy.
CABA has a Altman-Z score of -2.84. This is comparable to the rest of the industry: CABA outperforms 45.28% of its industry peers.
CABA has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
CABA's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. CABA outperforms 41.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.84 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 3.60 indicates that CABA has no problem at all paying its short term obligations.
CABA has a Current ratio (3.60) which is in line with its industry peers.
A Quick Ratio of 3.60 indicates that CABA has no problem at all paying its short term obligations.
CABA's Quick ratio of 3.60 is in line compared to the rest of the industry. CABA outperforms 45.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.6 | ||
| Quick Ratio | 3.6 |
3. Growth
3.1 Past
CABA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.67%.
EPS 1Y (TTM)-17.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 13.20% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.49%
EPS Next 2Y10.11%
EPS Next 3Y6.86%
EPS Next 5Y13.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CABA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CABA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.11%
EPS Next 3Y6.86%
5. Dividend
5.1 Amount
No dividends for CABA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:CABA (12/23/2025, 1:46:39 PM)
2.21
-0.18 (-7.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.3%
Inst Owner Change-1.64%
Ins Owners1.57%
Ins Owner Change0%
Market Cap212.76M
Revenue(TTM)N/A
Net Income(TTM)-158.52M
Analysts83.75
Price Target14.41 (552.04%)
Short Float %19.12%
Short Ratio3.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.77%
Min EPS beat(2)-10.16%
Max EPS beat(2)8.61%
EPS beat(4)1
Avg EPS beat(4)-2.23%
Min EPS beat(4)-10.16%
Max EPS beat(4)8.61%
EPS beat(8)1
Avg EPS beat(8)-3.9%
EPS beat(12)4
Avg EPS beat(12)-0.65%
EPS beat(16)8
Avg EPS beat(16)4.5%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.31%
PT rev (3m)22.24%
EPS NQ rev (1m)-3.46%
EPS NQ rev (3m)9.93%
EPS NY rev (1m)6.18%
EPS NY rev (3m)8.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.53 | ||
| P/tB | 1.53 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.53
EYN/A
EPS(NY)-1.84
Fwd EYN/A
FCF(TTM)-1.25
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0
BVpS1.45
TBVpS1.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -83.54% | ||
| ROE | -113.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-44.86%
ROA(5y)-40.06%
ROE(3y)-51.8%
ROE(5y)-45.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 28.76% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.6 | ||
| Quick Ratio | 3.6 | ||
| Altman-Z | -2.84 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)100.58%
Cap/Depr(5y)128.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.03%
EPS Next Y5.49%
EPS Next 2Y10.11%
EPS Next 3Y6.86%
EPS Next 5Y13.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-42.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.42%
EBIT Next 3Y-21.95%
EBIT Next 5YN/A
FCF growth 1Y-140.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-141.44%
OCF growth 3YN/A
OCF growth 5YN/A
CABALETTA BIO INC / CABA FAQ
What is the ChartMill fundamental rating of CABALETTA BIO INC (CABA) stock?
ChartMill assigns a fundamental rating of 1 / 10 to CABA.
Can you provide the valuation status for CABALETTA BIO INC?
ChartMill assigns a valuation rating of 0 / 10 to CABALETTA BIO INC (CABA). This can be considered as Overvalued.
How profitable is CABALETTA BIO INC (CABA) stock?
CABALETTA BIO INC (CABA) has a profitability rating of 0 / 10.